How does psoriasis impact wound healing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Psoriasis and Wound Healing: A Paradoxical Relationship

Psoriasis actually accelerates wound healing rather than impairing it, with involved and uninvolved psoriatic skin healing significantly faster than normal skin, though patients with psoriasis face increased risk of superficial surgical site infections after procedures like TKA. 1

The Core Paradox

The relationship between psoriasis and wound healing is counterintuitive. While psoriasis is fundamentally a chronic inflammatory disease driven by inappropriate T-cell and dendritic cell activation with subsequent cytokine release 2, this inflammatory milieu paradoxically enhances rather than impairs the wound healing process.

Accelerated Healing in Psoriatic Skin

Research demonstrates that both involved and uninvolved skin in psoriasis patients heals significantly more rapidly than normal skin 1. In a controlled study using 3mm punch biopsies, psoriatic skin showed measurably faster closure by day 6 compared to controls. This acceleration appears related to:

  • Altered NMDAR subunit expression: The NR2C subunit is down-regulated in the basal cell layer of psoriatic epidermis, while NR2D shows increased strong staining in uninvolved epidermis 1
  • Keratinocyte hyperproliferation: The same mechanisms driving psoriatic plaque formation (keratinocyte switching from differentiation to growth) facilitate rapid wound closure 1

The Infection Risk Caveat

Despite faster healing, psoriasis independently increases the risk of serious infections, and this risk is compounded by immune-modulatory treatments 3. Most critically for surgical planning:

  • Superficial surgical site infection (SSI) risk is significantly elevated (OR 1.74 overall; OR 2.83 for superficial SSI specifically) after procedures like primary TKA 4
  • Deep SSI risk is not significantly increased 4
  • The absolute risk of serious infection remains low despite the relative increase 3

Clinical Implications for Wound Management

Perioperative Considerations

For low-risk surgical procedures: Continue immune-modulatory treatments (infliximab, adalimumab, etanercept, methotrexate, ciclosporin) through the perioperative period 3

For moderate- and high-risk surgeries: Use individualized risk assessment considering:

  • Patient-specific comorbidities (diabetes, obesity, cardiovascular disease) 5
  • Type and degree of immune suppression
  • Infection history
  • Need for psoriasis control 3

The Wound Healing Mechanism

The pathophysiology suggests that psoriasis represents a dysregulation of normal wound healing mechanisms rather than impaired healing 6, 7. Specifically:

  • Normal wound healing requires precise coordination between keratinocyte proliferation and differentiation
  • In psoriasis, there is a lack of inhibition of the proliferative phase, leading to both accelerated wound closure and psoriatic plaque formation 6
  • Langerhans cells may trigger this process through dysregulated nitric oxide and epidermal growth factor production 7

Gene Expression Patterns

Recent molecular analysis reveals that psoriatic skin shows:

  • Upregulation of inflammatory cytokines (IL17A, TNF) and matrix remodeling enzymes (MMP9) 8
  • Increased expression of KRT16 and CD44, genes associated with wound healing and keratinocyte proliferation 8
  • These patterns explain both the rapid healing and the chronic inflammatory nature of the disease

Practical Management Algorithm

Step 1: Recognize that wound healing itself is not impaired—it's accelerated

Step 2: Focus infection prevention strategies on:

  • Optimizing metabolic comorbidities (diabetes control, cardiovascular risk factors) 5
  • Considering temporary modification of immune-modulatory therapy only for moderate-to-high risk surgeries 3
  • Enhanced wound surveillance for superficial infections post-operatively 4

Step 3: For active psoriatic lesions near surgical sites:

  • Treat aggressively pre-operatively to reduce local inflammation
  • Recognize that the underlying healing capacity is preserved 1

Key Pitfalls to Avoid

  • Do not assume impaired healing: The inflammatory milieu in psoriasis enhances rather than impairs wound closure 1
  • Do not unnecessarily stop biologics: For low-risk procedures, continuing therapy is safe and maintains disease control 3
  • Do not ignore infection risk: While healing is faster, superficial SSI risk is genuinely elevated and requires vigilance 4
  • Do not overlook systemic comorbidities: The chronic inflammation underlying psoriasis contributes to cardiovascular disease, metabolic syndrome, and other conditions that genuinely impair healing 2, 5

References

1
Research

The rate of wound healing is increased in psoriasis.

Journal of dermatological science, 2013

3
Research

Psoriasis and infection. A clinical practice narrative.

The Australasian journal of dermatology, 2019

4
Research

Psoriasis Is a Risk Factor for Surgical Site Infection After Primary TKA.

Clinical orthopaedics and related research, 2024

Related Questions

What is the appropriate treatment for a 60-year-old man with psoriasis limited to both arms and the face?
How should a psoriasis flare triggered by an antibiotic be managed?
Which biologic agents are safe for treating psoriasis in a breastfeeding mother?
Are there special shampoos and conditioners I can use in addition to my prescribed topical medication to help manage my scalp psoriasis?
What is the most likely cause of the red‑brown macules on the palms and soles in a 40‑year‑old man with known knee psoriasis?
What is the prognosis and expected survival for a 30‑year‑old Black male, 6′5″, 318 lb, with hypertension treated with amlodipine, normal CBC and CMP, eGFR 87‑93 mL/min/1.73 m², creatinine 1.12‑1.33 mg/dL, low‑grade troponin elevations, normal 12‑lead electrocardiogram, spine MRI suggesting possible autoimmune or demyelinating disease, brain MRI showing confluent periventricular ischemic leukoencephalopathy interpreted as likely autoimmune, positive antinuclear antibodies with RNP antibodies, G6PD deficiency, normal liver enzymes, mildly elevated ESR, CK, and CRP, pending sleep‑apnea testing and Cushing’s work‑up, and upcoming electromyography?
What are the effects and risks of combining NyQuil (acetaminophen, dextromethorphan, doxylamine) with Mucinex (guaifenesin) in a patient?
What are the normal values of cerebral blood flow (CBF) and how is it calculated?
In an adult with severe insomnia for two weeks despite multiple oral agents and a nightly dose of suvorexant 10 mg, can emergency department staff safely induce sleep using intravenous medications?
What are the recommended TNF‑α inhibitors, their dosing regimens and administration frequencies, and their brand names (with generic names)?
What is the recommended treatment for hyperkeratosis of wound edges in psoriasis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.